Clinical Trials on Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Belgium

Total 156 results

Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
University Hospital, Antwerp
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (ECLYPS)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region

Belgium, Netherlands
Incyte Corporation

Active, not recruiting

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) Malignancies

United States, Netherlands, Spain, United Kingdom, Belgium, Austria
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
European Organisation for Research and Treatment...
Merck KGaA, Darmstadt, Germany

Recruiting

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (RAVINA)

Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Belgium, Netherlands, Norway, United Kingdom, Ireland, Italy, Slovenia, Germany, Spain
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, Italy, Canada, Korea, Republic of, United Kingdom, Germany, Vietnam, Japan, France, India, Taiwan, Thailand, Malaysia, Turkey, Brazil, Belgium, Poland, Austria, Hungary
Cliniques universitaires Saint-Luc- Université...

Recruiting

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (UCL-Xenog)

Squamous Cell Carcinoma of the Head and Neck

Belgium
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
Cliniques universitaires Saint-Luc- Université...

Recruiting

Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients

Squamous Cell Carcinoma of the Head and Neck

Belgium
Cliniques universitaires Saint-Luc- Université...

Terminated

Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (CETLEE011)

Squamous Cell Carcinoma of the Head and Neck

Belgium
Genmab

Completed

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Head and Neck Cancer

United Kingdom, Belgium, Slovakia, Hungary
EMD Serono

Completed

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Cancer

Czech Republic, France, United Kingdom, Belgium, Hungary, United States, Poland, Slovakia
Genentech, Inc.

Completed

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Head and Neck Cancer

Belgium, United States
Universitaire Ziekenhuizen KU Leuven
AstraZeneca; European Organisation for Research and Treatment of Cancer - EORTC and other collaborators

Active, not recruiting

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO)

Oral Cavity Squamous Cell Carcinoma

Belgium
Amgen
Merck Sharp & Dohme LLC

Completed

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (MASTERKEY232)

Carcinoma of the Head and Neck

United States, Canada, Switzerland, France, Spain, United Kingdom, Italy, Belgium, Austria, Australia, Greece
Cliniques universitaires Saint-Luc- Université...

Recruiting

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (HN1901)

Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

Belgium
Cliniques universitaires Saint-Luc- Université...

Completed

Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RACATREX)

Squamous Cell Carcinoma of the Head and Neck

Belgium, Luxembourg
European Organisation for Research and Treatment...
Boehringer Ingelheim

Completed

Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

Belgium, Italy
Universitaire Ziekenhuizen KU Leuven
Flemish League Against Cancer

Terminated

Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

Belgium
Genentech, Inc.

Completed

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Head and Neck Cancer

United States, Germany, Spain, France, Australia, Hungary, Belgium, Bulgaria, United Kingdom, Italy, Romania
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

United States, Canada, France, Spain, Belgium, Czechia, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Australia, Germany, Georgia, Israel
Jules Bordet Institute
Innate Pharma

Withdrawn

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA (ARTEMIS-Eso)

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus

Belgium
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Centre Hospitalier Universitaire Dinant Godinne...

Not yet recruiting

Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy (TGV-PI)

Head and Neck Squamous Cell Carcinoma | Tumor Growth

Belgium
AstraZeneca

Completed

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Squamous Cell Carcinoma of the Head and Neck

Croatia, Sweden, United States, Czech Republic, Italy, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Latvia, Lithuania, Norway, Canada, Netherlands, Argentina, Belgium, Greece, Thailand, India, Israel, Malaysia, ... and more
Jules Bordet Institute

Active, not recruiting

Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer (StomRay)

Head and Neck Squamous Cell Carcinoma

Belgium
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Head and Neck Cancer

France, Russian Federation, Spain, United Kingdom, Germany, Hungary, Poland, Ukraine, Austria, Netherlands, Slovakia, Sweden, Switzerland, Belgium, Italy, Portugal, Czech Republic
Pfizer

Terminated

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, China, Taiwan, France, Australia, Hungary, Korea, Republic of, Germany, Japan, Switzerland, Ireland, Israel, United Kingdom, Italy, Poland, Belgium, Canada, Greece, Portugal, Austria, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Bristol-Myers Squibb

Completed

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

Head and Neck Cancer

United States, Brazil, Italy, South Africa, Spain, Canada, Argentina, Belgium, Chile, Czechia, Finland, France, Ireland, Mexico, Netherlands, Norway, Romania, Russian Federation, Sweden, Turkey, United Kingdom
Cliniques universitaires Saint-Luc- Université...

Completed

Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery (HNSCC)

Surgery | Head and Neck Squamous Cell Carcinoma | Growth Factor

Belgium
European Organisation for Research and Treatment...
Danish Head and Neck Cancer Group

Active, not recruiting

AF CRT +/- Nimorazole in HNSCC

Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers

Belgium, France, Poland, Australia, Germany, Netherlands, Switzerland
University Hospital, Ghent

Completed

Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck

Primary Non-operated Squamous Cell Carcinoma of Oral Cavity | Primary Non-operated Squamous Cell Carcinoma of Oropharynx | Primary Non-operated Squamous Cell Carcinoma of Hypopharynx | Primary Non-operated Squamous Cell Carcinoma of Larynx

Belgium
University Hospital, Ghent

Completed

Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer. (C-ART-2)

Primary Non-operated Squamous Cell Carcinoma of Oral Cavity | Primary Non-operated Squamous Cell Carcinoma of Oropharynx | Primary Non-operated Squamous Cell Carcinoma of Hypopharynx | Primary Non-operated Squamous Cell Carcinoma of Larynx

Belgium
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
Cliniques universitaires Saint-Luc- Université...
University Hospital, Rouen; University Hospital, Montpellier; Central Hospital... and other collaborators

Unknown

Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma (pet)

Head and Neck Squamous Cell Carcinoma

Belgium
Symphogen A/S

Completed

Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Carcinoma, Squamous Cell of Head and Neck

Belgium, France, Germany
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Belgium, Spain, Australia
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Metastatic Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck (SCCHN)

France, Belgium, Spain, Germany, Italy, Canada, United States
Universitaire Ziekenhuizen KU Leuven
KU Leuven; Stichting tegen Kanker

Recruiting

Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC (SEMIRAHN)

Squamous Cell Carcinoma of Head and Neck

Belgium
Ipsen

Terminated

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Gastric Cancer | Colorectal Cancer | Bone Cancer | Squamous Cell Carcinoma of the Head and Neck | Advanced Cancer | Recurrent Disease | Pancreatic Ductal Adenocarcinoma | Metastatic Tumours

United States, France, Belgium, Switzerland, Netherlands
AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
European Organisation for Research and Treatment...

Active, not recruiting

Biomarker-based Study in R/M SCCHN (UPSTREAM)

Carcinoma, Squamous Cell of Head and Neck

France, Spain, Belgium, Italy, United Kingdom
Glycotope GmbH

Completed

CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer (RESGEX)

Carcinoma, Squamous Cell of Head and Neck

Belgium, France, Germany, Italy, Poland, Romania, Spain
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Korea, Republic of, United Kingdom, Spain, Belgium, Singapore, Canada, Netherlands, Australia
Exelixis

Recruiting

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)

Head and Neck Squamous Cell Carcinoma

United States, Belgium, Bulgaria, France, Italy, Korea, Republic of, Romania, Slovakia

Clinical Trials on Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations